Understanding the uptake of a drug by diseased tissue, and the drug's subsequent spatiotemporal distribution, are central factors in the development of effective targeted therapies. However, the interaction between the pathophysiology of diseased tissue and individual therapeutic agents can be complex, and can vary across tissue types and across subjects. Here, we show that the combination of mathematical modelling, high-resolution optical imaging of intact and optically cleared tumour tissue from animal models, and in vivo imaging of vascular perfusion predicts the heterogeneous uptake, by large tissue samples, of specific therapeutic agents, as well as their spatiotemporal distribution. In particular, by using murine models of colorectal cancer and glioma, we report and validate predictions of steady-state blood flow and intravascular and interstitial fluid pressure in tumours, of the spatially heterogeneous uptake of chelated gadolinium by tumours, and of the effect of a vascular disrupting agent on tumour vasculature.
M athematical modelling of biological tissue is increasingly used to better understand complex biological phenomena, such as the development of disease 1 . This developing paradigm of computational experimentation can enable subtle interventions to be performed in a manner that would be challenging or impossible in a conventional experimental setting. In this study we present a framework for performing realistic computational experiments that naturally incorporates the variability and heterogeneity found between biological samples. It allows large tissue samples to be imaged and treated as living specimens, by combining cuttingedge optical and in vivo imaging techniques with mathematical modelling. We have named our framework REANIMATE ('realistic numerical image-based modelling of biological tissue substrates') (see Fig. 1 for an overview diagram).
Optical imaging of cleared tissue can provide 3D data detailing complex interacting structures (such as blood vessel networks, cell nuclei, and so on), which can be explored, across entire organs 2,3 and at resolutions of a few micrometres 4 , by using fluorescently labelled probes that bind to specific structures. Our use of large, highresolution structural images in computational simulations, rather than relying on small isolated samples or synthetically generated substrates, is a key development, and has required the development of new image analysis and computational modelling approaches. Furthermore, by incorporating in vivo imaging (in particular, magnetic resonance imaging, MRI), REANIMATE can incorporate quantitative measurements.
Capturing the physiological variation in complete tissue specimens is particularly useful in tumours, which can be highly heterogeneous, between tumour types and tumour deposits, and even within individual tumours 5 . This results in substantial differences, for example in drug delivery, oxygenation and gene expression 6 , with associated differences in therapeutic response and resistance. Effective therapy normally requires drugs to be delivered to the site of disease at as high a concentration as possible, but avoiding significant toxicity effects in healthy tissues, while sub-optimal exposure can limit treatment efficacy, induce exposure-mediated resistance mechanisms 7 , or even stimulate tumour growth 8 .
This complex physiological-pharmacological landscape requires careful analysis in order to be fully understood. The numerical modelling component of REANIMATE consists of two steps. First, a solution is sought from a set of coupled fluid dynamics models that describe steady-state vascular and interstitial fluid transport. Second, the steady-state solution (or set of solutions) is used to parameterize a time-dependent model that describes the vascular and interstitial uptake of exogenously administered material. This can be used, for example, to model the heterogeneous pharmacokinetics of drug or imaging contrast agents, or the delivery of individual particles (for example T cells, antibodies), and terms can be introduced to describe drug targeting and metabolism.
For the predictions made by our, or any, computational experiments to be confidently accepted, careful experimental validation must be performed. As a first evaluation, we have used REANIMATE to (1) study the spatially heterogeneous uptake of a gadoliniumbased MRI compound (which allowed us to compare numerical modelling solutions with ground-truth in vivo data) and (2) investigate the effect of the vascular disrupting agent (VDA) OXi4503 on tumour vasculature. These results provided a rich, 3D framework for probing spatially heterogeneous tumour drug delivery and the treatment response.
REANIMATE steady-state simulation in subcutaneous colorectal carcinoma xenografts. Our next aim was to use whole-tumour blood vessel networks as the substrate for simulations of steady-state fluid dynamics. Our mathematical model is composed of coupled intravascular and interstitial compartments, with exchange mediated by vascular permeability and described by Starling's Law. Blood flow and interstitial delivery were modelled using Poiseuille flow and Darcy's law, respectively, and the model was optimized over the entire tumour through the prescription of the pressure boundary conditions at peritumoral boundary vessels. We performed our initial simulations on a set of LS174T and SW1222 colorectal adenocarcinoma xenografts.
As shown in the summary of simulated parameter values in Supplementary Table 1 , solutions to our mathematical model predicted significant differences between SW1222 and LS174T tumours, in blood flow, blood velocity and vessel wall sheer stress, which are consistent with their known characteristics. Example spatial distributions of each of these REANIMATE parameters are shown in Fig. 3 , in which vascular parameters (blood flow and pressure) are displayed as coloured vessel segments and interstitial (1) , which can be performed longitudinally during tumour growth, tumours are resected and optically cleared (2) , to render tumours transparent for three-dimensional (3D) fluorescence imaging. Optical images are processed to segment fluorescently labelled structures within the tumour microenvironment (3) (in this case, blood vessel networks), which are reconstructed in 3D graph format (nodes and connecting segments, each with a radius corresponding to the size of the blood vessel). These geometrical data become the substrate for computational fluid dynamic models to estimate steady-state blood flow and interstitial transport (4) and time-dependent numerical modelling of drug delivery (5) . All of these data can then be used to perform in silico experiments (for example, assessing the heterogeneous delivery of drugs or contrast agents), which can be compared with in vivo experiments in the same tumour models, or even the same mice. In this study, REANIMATE is used to study the action of a VDA (OXi4503) in two models of human colorectal carcinoma. parameters (interstitial fluid pressure (IFP), interstitial fluid velocity (IFV) and perfusion) as overlaid colour fields. Results are shown for example LS174T ( Fig. 3a -e) and SW1222 tumours ( Fig. 3f-j) .
Key to the interpretation of these results was our ability to compare them directly with equivalent in vivo imaging data (in this case arterial spin labelling magnetic resonance imaging, ASL-MRI), which can be used to quantify perfusion, non-invasively 9 . Perfusion is a measure of the rate of delivery of fluid to biological tissue, and is dependent on blood flow, vascular permeability and interstitial density, among other factors 18 . Comparisons of ASL-MRI in vivo measurements and REANIMATE predictions are shown in Fig.  3c (LS174T) and 3h (SW1222), which shows a clear correspondence between the two data types. Statistical analysis revealed no significant differences between predicted and measured perfusion values (P < 0.01, Kolmogorov-Smirnov). Scatter plots of both measurements are shown in Supplementary Fig. 1a ,b, which revealed a significant correlation between the two measurements (LS174T, r 2 = 0.82, P < 0.001; SW1222 r 2 = 0.89, P < 0.001; Pearson test). Similarly, in both in vivo measurements and simulations, perfusion was distributed heterogeneously throughout the tumours, with markedly raised values at the periphery of both types of colorectal tumour. This spatial distribution is characteristic of solid tumours, particularly subcutaneous xenograft models 19 . However, some regional differences were also evident between simulated and ASL perfusion values, but which could have been caused by errors in either value, and/or errors in the spatial registration of the two types of data.
Both in vivo measurements and simulations showed that SW1222 tumours were better perfused than LS174T tumours, which is again consistent with the results of previous studies 20 . However, perfusion at the centre of SW1222 tumours was much greater than in LS174T tumours, both in simulations and in vivo data. On average, we found that simulated perfusion values in LS174T tumours matched those measured in vivo with MRI (0.18 ± 0.07 and 0.19 ± 0.08 ml g −1 min −1 ) for simulated and in vivo measurements, respectively, while SW1222 estimates were slightly larger, but of the same order as in vivo measurements (0.33 ± 0.18 and 0.73 ± 0.03 ml g −1 min −1 ). REANIMATE also predicted elevated IFP in both tumour types, with typical values in the range 12-25 mm Hg in the centre of tumours, and which declined towards the periphery. This, again, is consistent with the known characteristics of these types of tumour, and no significant difference was measured between LS174T and SW1222 tumours 21 . However, in both tumour types, IFP was not uniformly distributed, but instead varied by up to 10 mm Hg within the centre of individual tumours. IFP was raised at the location of perfused vasculature, producing intratumoral advection effects (as can be seen in the interstitial velocity images in Fig. 3e,j) . These results agree with previous measurements of IFP and IFV from our own laboratory, in which mean IFP was measured to be 16 ± 5 mm Hg in LS174T tumours and 13 ± 2 m Hg in SW1222 tumours, for a tumour volume of 0.1 cm 3 (ref. 21 ).
As our optimization procedure for the assignment of pressure boundary condition has a potentially large number of solutions, we sought to determine the variability observed in vascular pressure predictions across multiple simulation runs. This experiment, described in the Supplementary Information, found that the mean standard deviation of vascular pressure predictions, across simulation runs, was 0.25 mm Hg and 0.49 mm Hg in LS174T and SW1222 tumours, respectively. This is much smaller than the variability associated with spatial heterogeneity within the tumours (8.8 and 9.2 mm Hg, respectively).
REANIMATE steady-state simulation in an orthotopic murine glioma model. To evaluate the generalizability of the REANIMATE framework, we next applied it to data from orthotopic murine glioma tumours, derived from the murine GL261 cell line. At 20 days following the injection of glioma cells into the brain, tumours were resected from mice with a section of normal cortex tissue attached. Segmented tumour and cortex vessels are shown in Fig. 4a , with brain vessels labelled in blue and tumour vessels in red.
As with colorectal tumours, steady-state vascular and interstitial REANIMATE fluid flow solutions were generated ( Fig.  4b-f ). The simulations predicted raised IFP within the tumour (mean, 16 ± 10 mm Hg), and a mean interstitial perfusion of 1.3 ± 0.5 ml min −1 g −1 . Comparison of these simulation results with in vivo measurements using ASL-MRI ( Fig. 4d ) revealed a good correspondence, with a mean measured tumour perfusion of 1.1 ± 0.7 ml min −1 g −1 , and equivalent spatial distribution (hyperperfused periphery and central hypoperfusion). A scatter plot of the data is shown in Supplementary Fig. 1c , which revealed a significant correlation between the two measurements (r 2 = 0.91, P < 0.001, Pearson test).
Compared with subcutaneous tumours, REANIMATE predicted orthotopic gliomas to have a more uniform central IFP, which varied within a range of ± 4 mm Hg. IFV was correspondingly low in the centre (< 0.01 µ m s −1 ) and high at the periphery (indeed, much higher than in subcutaneous tumours (17 ± 4 µ m s −1 )). No measurements of IFP or IFV exist in the literature against which these data can be compared, presumably due to the technical challenges associated with their measurement in deep-seated tumours.
In combination, these results demonstrate that mathematical modelling of fluid dynamics, using optical image data from cleared tumour tissue as a substrate, is both feasible and provides quantitative predictions of vascular perfusion that are in keeping with experimental results. Therefore our next step was to use the steadystate flow predictions to parameterize a time-dependent model to simulate the delivery of exogenously administered material.
REANIMATE prediction of Gd-DTPA delivery. As a first evaluation, we chose to model the dynamics of chelated gadolinium (Gd-DTPA), a widely used MRI contrast agent with well-studied pharmacokinetics, and directly compare them with in vivo measurements. Gd-DTPA can be thought of as a proxy for a non-metabolized therapeutic agent. Time-dependent simulations were calculated using a 'propagating front' algorithm that used steady-state solutions to mimic the physical delivery of material, both via vascular flow and by diffusion across the blood vessel wall and through the interstitium. To provide ground-truth data for comparison, and to generate new modelling substrates, we performed in vivo experiments to measure the delivery of a bolus of Gd-DTPA in a set of LS174T (n = 5) and SW1222 (n = 6) tumours, using a dynamic contrastenhanced (DCE) MRI sequence ( Fig. 5 ). Following these measurements, mice were killed via cervical dislocation. We resected and set two tumours aside (one LS174T and one SW1222) for processing within the REANIMATE framework.
Steady-state simulations were performed as described above, and were used as the basis for time-dependent delivery simulations. The influence of each vessel network inlet was modelled independently, and an algorithm was developed that monitored a propagating front through the network. Exchange between the vascular and interstitium was cast in a finite element framework, with vessel permeability (to Gd-DTPA flux) initially fixed at 1 × 10 −6 cm s −1 (refs 22, 23 ). The interstitium was modelled as a continuum with a constant cell volume fraction (f c = 0.8; ref. 24 ). Gd-DTPA does not cross the cell membrane 25 , and so Gd-DTPA concentration ([Gd]) was scaled by the fractional volume of the extracellular space, and we assumed a constant diffusion through the interstitium (D = 2.08 × 10 −4 mm 2 s −1 ; ref. 26 ). Both in vivo measurements and simulations had a duration of 12 min, with a temporal resolution of 16 s. Simulations were driven by a bi-exponential vascular input function, taken from the literature 27 . Initially, 1% of the entire dose of the input function was partitioned across all tumour inlets, weighted by the inflow rate for the individual inlet.
REANIMATE intravascular and interstitial Gd-DTPA delivery predictions were rendered as videos (Supplementary Videos 1 and 2). Virtual sections from an LS174T tumour are also shown in Fig. 5a , which show a prolonged, peripheral enhancement pattern, which is typical of the tumour type 20 . In Fig. 5b we show plots of contrast agent uptake, in which the greyscale colouring of each curve represents distance from the tumour edge (darkest at the edge, lightest in the centre). These reveal a highly heterogeneous enhancement pattern, with decreasing concentration for increasing proximity to the tumour centre. Conversely, we found that SW1222 tumours were enhanced with Gd-DTPA much more rapidly and homogeneously, with a peak enhancement at around 4 min, followed by a washout phase ( Supplementary Fig. 2 ).
REANIMATE solutions describing Gd-DTPA delivery were analysed in the same manner as the experimental data, that is, as a function of distance from the tumour periphery. Simulations were performed in two stages: the first estimated Gd-DTPA enhancement using the initialization parameter values defined above (the naive solution), and the second stage used modified parameter values, based on iteratively minimizing the disparity between simulated and in vivo data.
Our naive analysis underestimated the magnitude of contrast enhancement in the LS174T tumours, but still reflected their spatial heterogeneity, with the S 0 parameter decreasing with distance from the tumour periphery. The enhancement rate parameter, r 1 , provided a good fit to in vivo data, but did not reflect its increasing value at the tumour centre. To account for this, we increased the mean vascular permeability to 0.9 × 10 −6 cm s −1 at the periphery, with a linear increase to 1.1 × 10 −6 cm s −1 in the centre, which provided a better accordance with in vivo data ( Supplementary  Fig. 3 ). For the SW1222 tumour naive simulation, contrast agent uptake was overestimated, but homogeneously distributed, 
Fig. 4 | REANiMATE simulations of steady-state fluid dynamics (vascular and interstitial) in an orthotopic murine glioma model (GL261). a,
Segmented blood vessel networks, showing tumour vessels (red) and normal brain vessels (blue). The tumour was connected to the brain via several large feeding vessels at the interface between the two tissues. b, The results of REANIMATE vascular simulations, with vessel network colour-coded for vessel radius, vascular pressure and blood flow. c, A 3D rendering of REANIMATE IFP predictions, with blood vessel network overlaid. d, Comparison of in vivo perfusion measurements with ASL-MRI and REANIMATE predictions. A scatter plot comparing ASL measurements of perfusion and REANIMATE predictions is shown in Supplementary Fig. 1c . A complete slice through the brain is shown for ASL-MRI, with the tumour outlined with a black dashed line. REANIMATE perfusion predictions show a slice through the tumour. e,f, REANIMATE predictions for IFP and IFV, respectively.
reflecting what was found in vivo. The rate of enhancement was also much greater than in vivo. We therefore uniformly decreased the vascular permeability to 0.75 × 10 −7 cm s −1 in the second simulation, which then provided a good accordance with in vivo data (P < 0.01, Kolmogorov-Smirnov). Scatter plots of the data ( Supplementary Fig. 1d ) also revealed a significant correlation (r 2 = 0.92, P < 0.001, Pearson). We therefore conclude from these experiments that REANIMATE can provide good estimates of the delivery of Gd-DTPA, but can be further improved by in vivo measurements.
Dual-fluorophore optical imaging of response to OXi4503 treatment. Using our optimized Gd-DTPA delivery data, we went on to investigate the ability of REANIMATE to model drug uptake and response to treatment. This required the development of a dual-fluorophore imaging technique that allowed measurements of tumour vascular structure at two separate time points to be encoded. We chose to model vascular targeting therapy, due to its rapid, well characterized mechanism of action, which can be captured with in vivo MRI 28 . The acute effects of VDAs have been well documented, using histology 29, 30 , MRI 31 and in vivo confocal microscopy 32 , which have demonstrated rapid vascular shutdown and extensive vessel fragmentation within the first 60 min to 24 h of administration. This causes decreased perfusion, especially in the central part of the tumour 31, 33 , and an associated increase in hypoxia and cell death 33 . In this study, we investigated a single 40 mg kg −1 dose of OXi4503.
Our dual-fluorophore method allowed us to characterize blood vessel structure at two separate time points, by administering fluorescently labelled lectin (AlexaFluor-568) just before injecting OXi4503, and then a second lectin 90 min later (AlexaFluor-647). Our rationale was that vessels occluded by OXi4503, and no longer perfused, would be labelled by only the first fluorophore; vessels that remained perfused following therapy would be labelled with both fluorophores. To validate our results, in vivo ASL-MRI was also performed on a subset of tumours (n = 3 of each tumour type). Mice, each bearing an LS174T or SW1222 tumour, were randomly assigned to treatment (OXi4503, 40 mg kg −1 ) or control (administered saline) groups. Figure 6a shows example volume renderings of dual-stained vessel networks, in which vessels were coloured blue if co-labelled with both fluorescent lectins (vessels that were perfused . Each curve shows the average uptake at a fractional distance between the perimeter and centre of mass of the tumour. c, Plot of a line profile through the tumour, at 13 min, corresponding to the black lines in a. d, Histogram of Gd-DTPA concentrations at 13 min (also shown as a scatter plot in Supplementary Fig. 1d ).
both pre-and at 90 min post-OXi4503 administration) or green if perfusion was evident pre-treatment but had been removed at 90 min. See Supplementary Video 3 for a 3D rendering of the data. Figure 6b -d documents the effect of OXi4503 on the geometry of LS174T and SW1222 vessel networks. Figure 6b compares the mean distance of blood vessels from the centre of each tumour type, preand post-treatment with OXi4503. This plot shows that, for LS174T tumours, vessel that became non-perfused with OXi4503 (vessels rendered in green) were generally located in the centre of tumours, whereas SW1222 displayed a more distributed and localized pattern of perfusion loss. Figure 6c plots the number of graphical nodes within each cluster that became isolated by this loss of perfusion, which was significantly different between LS174T and SW1222 tumours (LS174Ts displayed much larger clusters; P < 0.01). This further demonstrates the fragmented nature of the SW1222 tumours' response to OXi4503.
To ensure that these changes in vascular geometry were induced by the action of OXi4503, blood volume was measured pre-and post-OXi4503 and compared against control groups that received saline only. As can be seen in Fig. 6d , OXi4503 induced a significant decrease in both tumour types (P < 0.01), but in control tumours, no significant change was found (P > 0.05).
REANIMATE simulations of response to OXi4503.
Having identified significant differences between SW1222 and LS174T tumours in their vascular structural response to OXi4503, we next aimed to use REANIMATE to simulate changes in tumour perfusion and IFP induced by OXi4503, to attempt to further explore these differences. Figure 7a -c shows the results of REANIMATE simulations of vascular flow, IFP and interstitial perfusion in an example LS174T tumour, pre-and post-OXi4503. Each reveals a spatially heterogeneous response to the drug, with both increases and decreases in perfusion and IFP observed within the same tumours, representing a redistribution of flow in response to localized vascular occlusion.
These trends were replicated in in vivo ASL data (example images are shown in Fig. 7d ), which measured a significant decrease in median tumour perfusion of 9.8% (from 0.61 to 0.55 ml min −1 g −1 , P < 0.05) in LS174T tumours, but which was accompanied by a significant increase in the 90th percentile perfusion value (from 2.48 to 2.64 ml min −1 g −1 , P < 0.01). Our REANIMATE simulations also predicted a decrease in IFP of 4.5 mm Hg, but accompanied by an increase of 3.6 mm Hg in the 90th percentile. These results demonstrate a complex redistribution of flow caused by the VDA at this early time point, which we sought to better understand. In SW1222 tumours, in vivo measurements of perfusion and IFP did not significantly change. Moreover, the fragmented nature of dual-labelled fluorescence images meant that post-OXi4503 steady-state simulations could not be performed in SW1222 tumours. Our first REANIMATE computational experiment aimed to simulate the uptake of OXi4503, using a similar approach as taken for Gd-DTPA uptake simulations, but over a longer duration (90 min, with a temporal resolution of 10 s). OXi4503 has a molar mass of 332.35 g mol −1 (approximately one-third that of Gd-DTPA), so, using the Stoke-Einstein relation, D was set at 7.37 × 10 −5 mm 2 s −1 . Systemic pharmacokinetics for OXi4503 were taken from the literature 34 , and expressed as an exponential decay function (equation (15)). Both intravascular and interstitial drug concentrations were simulated, and the results are shown in Fig. 8a (see Supplementary Video 4 for a 4D representation). As with Gd-DTPA experiments, OXi4503 uptake was spatially heterogeneous.
We then used these REANIMATE simulations of OXi4503 uptake to test two hypotheses: (1) that vessels that receive the greatest OXi4503 exposure are more likely to become non-perfused; (2) that network geometry differences between tumour types could influence their response to VDA therapy.
To test the first hypothesis, we compared vessels from our duallabelled data sets that had lost perfusion post-OXi4503 (that is, were labelled with just one fluorophore) with their simulated exposure to OXi4503, as predicted by REANIMATE. The box plot in Fig. 8b displays the result of this analysis, where nodes connecting only non-perfused ('green') vessels had a significantly lower exposure to OXi4503 than nodes connecting a mixture of non-perfused and perfused ('blue') vessels (P < 0.05). Similarly, Fig. 8c-f show the location of perfused and non-perfused vessels and the cumulative exposure to OXi4503 at 90 min post-administration, which shows non-perfused regions with low OXi4503 exposure; on average non-perfused vessels exhibited a significantly lower simulated exposure than vessels that remained perfused (2.0 compared with 3.8 mM min m −2 ; P < 0.001). These results are inconsistent with our first hypothesis, that perfusion loss would be associated with greater OXi4503 exposure, and so the hypothesis was rejected. This led us to next evaluate our second hypothesis, and investigate differences in the vascular architecture of the two tumour types. In particular, we evaluated the functional connectivity of the two tumour types.
Functional (or logical) connectivity and redundancy measures describe the connectedness of individual vessel networks, following pathways of decreasing fluid pressure. Specifically, redundancy was measured by N, the mean number of viable alternative pathways for each node if the shortest path (based on flow velocity) were occluded, and r, the average additional distance that would be travelled. Connectivity was defined as the sum of the number of nodes upstream and the number of nodes downstream of a given node, divided by the total number of nodes in the network. Figure 8g ,h shows histograms comparing log(C) and r measurements in LS174T and SW1222 tumours. These data revealed that SW1222 tumours had significantly greater vascular connectivity than LS174T tumours (C = 0.15 ± 0.06 and 0.06 ± 0.05, respectively) (P < 0.01). They also display greater redundancy, with N = 1.9 ± 0.9 and 1.5 ± 0.7 and r = 1.02 ± 0.02 and 1.04 ± 0.05, for SW1222 and LS174T tumours, respectively. Regional connectivity was also mapped, with examples shown in Fig. 8i (LS174T tumour) and 8j (SW1222 tumour), in which nodes are scaled and colour-coded according to their connectivity measure. These clearly show the greater connectivity evident in this example SW1222 tumour than in the LS174T tumour. Referring back to the definitions of connectivity and redundancy above, these results suggest that, in LS174T tumours, vessels that become non-perfused due to targeting by a high concentration of OXi4503 can cause large vascular territories downstream to become non-perfused, due to their lack of connectivity. In SW1222 tumours, loss of perfusion can be compensated by rerouting flow through alternative routes, thanks to their high redundancy. This explanation, which requires further evaluation, would explain the different pattern of response observed in SW1222 and LS174T tumours, with LS174T tumours showing large regions of perfusion loss in dual-fluorophore data (particularly in their core), while SW1222 show a more distributed pattern with flow loss in individual vessels.
Discussion
Computational modelling of cancer has a relatively long history [35] [36] [37] [38] [39] , and has provided valuable improvements in our understanding of the development and treatment of cancer. As noted by Altrock, Liu and Michor, 'the power of mathematical modelling lies in its ability to reveal previously unknown or counterintuitive physical principles that might have been overlooked or missed by a qualitative approach to biology' 39 . Successes have been found in a range of areas, from modelling the dynamics of mutation acquisition 40 to multiscale modelling of the interaction between tumour cells and their microenvironment 41 . Previous, seminal studies have combined experimental and numerical approaches to study the relationship between tumour microstructure and the delivery of therapeutic agents 36, 37, 42 . A key observation from this work was that the chaotic organization of tumour blood vessels, their highly permeable vessel walls and missing or non-functioning lymphatics can result in elevated IFP and limited blood flow. Both effects, alongside high cell density and thick extracellular matrix, can conspire to limit the delivery of systemically administered therapeutic agents, and can therefore act as a source of therapeutic resistance 43 . Although these principles are well established, the complex manner in which these phenomena can interact and vary within real-world tumours, and how individual drugs of different sizes and physico-chemical properties are distributed, is not well understood. This points to a critical need for a better understanding of drug delivery to solid tumours, which could, at least in part, help to address the pharmaceutical industry's current low approval rate for new cancer therapies, for which the influence of delivery is often an overlooked factor 44, 45 . Equally, this knowledge could provide improvements in the clinical management of the wide range of tumour types encountered in the clinic and enable treatments to be more effectively personalized. This is an example of an area in which we believe our REANIMATE framework will find wide application.
In this study we have introduced REANIMATE, a large-scale, 3D imaging, modelling and analysis framework, which uses data from optical imaging of cleared tissue 16, 46, 47 to produce realistic substrates for computational modelling of fluid dynamics in the tumour microenvironment, optionally guided by in vivo imaging data. We applied REANIMATE to imaging data from murine models of colorectal cancer and glioma to simulate (1) steady-state fluid dynamics (blood flow, intravascular and interstitial fluid pressure), (2) uptake of the MRI contrast agent Gd-DTPA and (3) uptake and response to vascular-targeting treatment (OXi4503). Our results demonstrated the feasibility and accuracy of this whole-tissue approach to numerical modelling, which allows computational experiments to be performed on real-world tumours. A key advantage of this approach is the ability to directly compare modelling solutions with experimental measurements from the same tumours.
Although, in principle, any number of physiological phenomena could be incorporated into the REANIMATE framework, we initially focused on modelling intravascular and interstitial delivery. This used well-established biophysical models, but on a larger scale than has previously been undertaken, and using real-world vascular networks. A justification for simulations at this scale is provided by the multi-scale interactions evident in tumour fluid dynamics. For example, elevated IFP is maintained via a whole-tumour distribution of both vascular perfusion and interstitial drainage; similarly, perfusion is spatially heterogeneous, meaning that one tumour subregion can be very different to another.
Previous studies have used mathematical modelling approaches to study tumour blood and interstitial flow, and have often focused on their associated spatial heterogeneity 48 . For example, Baxter and Jain 36, 42 described raised, homogeneous IFP at the centre of tumours, which drops precipitously at the tumour periphery. This result was based, in part, on simulations of spherical, spatially homogeneous tumour vasculature. Numerous studies have subsequently incorporated more realistic vasculature into models stemming from Baxter and Jain's work, such as synthetically generated vascular networks [49] [50] [51] [52] [53] , using micro-X-ray computed tomography data from microvascular casts to model intravascular blood flow 54 , or using sub-networks from tumours, derived from imaging data [55] [56] [57] . Synthetically generated vasculature, using angiogenesis models, has been used to formulate hypotheses on the delivery of chemotherapeutics 58, 59 , investigate the impact of tumour size on chemotherapeutic efficacy 60 and to investigate the effect of dynamic vasculature 50 and the structure and morphology of vascular networks 61 on drug delivery. REANIMATE builds on and extends this work by including simulation substrates from complete, real-world tumours, in three spatial dimensions, which are guided by and compared against in vivo measurements. In this initial demonstration, we focused on the vasculature of colorectal xenograft models, which we imaged by labelling with fluorescent lectin, allowing blood and interstitial flow to be explicitly simulated in realistic networks. We treated the interstitium as a continuum, but future generations of the framework could include additional structural elements such as cell membranes and nuclei, by multifluorescence labelling. Indeed, there is significant potential for extending and enhancing REANIMATE in other pathologies, to allow more in-depth computational experiments to be performed.
A key advantage of REANIMATE is its ability to compare model predictions with experimental measurements from the same tumours. We found a good correspondence between our predictions of vascular perfusion and delivery of Gd-DTPA, and those from in vivo imaging, both in their magnitude and spatial distribution. Perfusion was predicted to be significantly greater in SW1222 tumours than in LS174T tumours, which reflects the results of in vivo ASL measurements, and was highly heterogeneous, with flow concentrated at the periphery of both tumour types. Conversely, Gd-DTPA uptake was more heterogeneous in LS174T than SW1222 tumours, both in in vivo MRI measurements and simulations (with minimal parameter optimization).
Through its use of real-world, whole-tumour substrates, REANIMATE undertakes modelling at a whole-tissue scale. In many organs, this would enable pressure boundary conditions to be defined in a straightforward manner, potentially by directly measuring inlet and outlet pressures. However, subcutaneous tumour xenograft models normally exhibit a large number of small feeding vessels, and so explicitly measuring and defining pressure boundary conditions in this context is challenging. Our pressure boundary condition optimization procedure was a pragmatic solution to this problem, and enabled the use of target average pressures. We found that the variability of pressure predictions (from which all other parameters are ultimately derived) was much lower than the variability associated with spatial heterogeneity within the tumour. However, this approach could still provide a source of error and, while our model solutions agreed well with experimental measures, better approaches could doubtless be developed. For example, as suggested above, the use of tumours with a small number of welldefined inlet and outlet vessels, with measurable pressures, would be advantageous, and the use of complete tumour vascular networks would enable such an approach to be realized.
In summary, the results of this study show that, by adding realistic, whole-tumour microstructure, with its inherent heterogeneity, accurate predictions for tumour fluid dynamics and material delivery can be made. These results are important, as Gd-DTPA can be thought of as a proxy for delivery of a (non-metabolized) drug, enabling the accuracy of REANIMATE delivery predictions to be verified. Indeed, REANIMATE could easily be modified to include terms for metabolism, and acute response by the microenvironment could be modelled by modifying cell density terms. This could therefore allow panels of drugs to be assessed, with different delivery characteristics, to predict candidates that are most (or least) likely to achieve a therapeutic response.
To further investigate this ability, we used REANIMATE to study the response of our colorectal xenografts to OXi4503 treatment, and showed that structural connectivity and redundancy in colorectal tumour xenograft model vascular networks can introduce different responses to the vascular-targeting agent OXi4503. SW1222 tumours, with their greater connectivity and redundancy, are more able to resist loss of flow in individual vessels, by rerouting flow via local pathways, whereas there is much greater potential for LS174T tumours to lose perfusion in large downstream sub-networks. These results reflect those that we have previously observed in vivo when assessing the response of colorectal metastases to OXi4503 treatment in the liver 9 , in which the magnitude of the response decreased with increasing distance of individual tumours from major blood vessels. From a computational modelling perspective, these results are also relevant, as they demonstrate a mechanism through which tumours can become resistant to drug therapies, and which manifests via complex interactions across large regions within a tumour, or across whole organs.
These results each demonstrate the significance of large, realistic tumour simulations, of the form developed here with REANIMATE. The detailed insights generated in this study could not have been made with conventional 2D analysis of histological sections, or in vivo experiments that lack the spatial resolution and functional information to access this information, and demonstrates a key strength of the REANIMATE approach. We anticipate that REANIMATE will enable us to further study and understand complex interactions between biological phenomena, allowing new insights into key challenges in cancer research. While the limitations to drug delivery caused by the physiological structuring of tumours have been well studied 48, 62 , REANIMATE could enable a better understanding of limitations in tumour drug delivery in individual tumours (and how this can be mediated) 36, 63 and the development of resistance to therapy via physical (rather than biochemical) mechanisms 64 . Moreover, if applied to biopsy samples, or resected intact tumours (or tumour deposits), it could provide useful insights into treatment stratification in the clinic.
Methods
Tumor xenograft models. All experimental procedures were performed as detailed in UK Home Office project licence no. 70 6481 (approved and granted by the UK Home Office), and in accordance with the UK Home Office Animals Scientific Procedures Act 1986 and the UK National Cancer Research Institute (NCRI) guidelines 65 . Eight-to ten-week-old, female, immune-compromised nu/nu nude mice (background CD1) were used throughout this study (Charles River Laboratories). Human colorectal adenocarcinoma cell lines (SW1222 and LS147T) were cultured in complete medium (minimum essential medium Eagle with l-glutamine (EMEM) (Lonza) + 10% fetal bovine serum (Invitrogen)) in the ratio 1:20 (vol/vol) and incubated at 37 °C and 5% CO 2 . To prepare for injection, cells were washed with Dulbecco's phosphate buffered saline and detached with trypsin-EDTA (7-8 min, 37 °C, 5% CO 2 ). A 100 µ l bolus of 5 × 10 6 cells was injected subcutaneously into the right flank above the hind leg. Tumour growth was measured daily with callipers, for between 10 and 14 days.
Orthotopic glioma models. Female, eight-week-old, C57BL/6 mice were injected with 2 × 10 4 GL261 mouse glioma cells. Mice were anaesthetised with 4% isoflurane in an induction box and then transferred to a stereotactic frame (David Kopf Instrument), where anaesthesia was delivered through a nose cone and maintained at 2%. The head was sterilized with 4% chlorhexidine and the skin was cut with a sterile scalpel to expose the skull. Coordinates were taken using a blunt syringe (Hamilton, 75N, 26s/2″ /3, 5 μ l), 2 mm right and 1 mm anterior to the bregma, corresponding to the right caudate nucleus. A burr hole was made using a 25gauge needle. The Hamilton syringe was lowered 4 mm below the dura surface and then retracted by 1 mm to form a small reservoir, and 2 × 10 4 GL261 cells were injected in a volume of 2 μ l over 2 min. After leaving the needle in place for 2 min, it was retracted at a rate of 1 mm min −1 . The burr hole was closed with bone wax (Aesculap, Braun) and the scalp wound was closed using Vicryl Ethicon 6/0 suture.
Fluorescent labelling of tumour vasculature and perfusion fixation.
Lectin (Griffonia simplicifolia) bound to either Alexa-647 (Thermo Fisher Scientific, L32451) or Alexa-568 (Thermo Fisher Scientific, L32458) was injected intravenously (i.v.) and allowed to circulate for 5 min before perfusion fixation to allow sufficient binding to the vascular endothelium 2 .
To prevent blood clot formation within the vasculature, mice were individually heparinized by intraperitoneal (i.p.) injection (0.2 ml, with 1,000 IU ml −1 ). Mice were terminally anaesthetized by i.p. injection of 100 mg kg −1 sodium pentobarbital (Animalcare, Pentoject) diluted in 0.1 ml phosphate buffered saline (PBS). Once anaesthesia was confirmed, surgical procedures for intracardial perfusion were performed for systemic clearance of blood. PBS (30 ml, maintained at 37 °C) was administered with a perfusion pump (Watson Marlow, 5058) at a flow rate of 3 ml min −1 to mimic normal blood flow. After the complete drainage of blood, 40 ml of 4% paraformaldehyde (PFA, VWR chemicals) was administered. Harvested tumours were stored for 12 h in 4% PFA (10 ml total volume, at 4 °C).
Treatment with OXi4503. Following 10-14 days of growth, mice were randomly assigned to treatment (OXi4503, n = 6) and control (saline) groups, with n = 3 SW122 and n = 3 LS174T in each. Treated groups were injected i.v. with 100 µ g lectin-AlexaFluor 647 diluted in sterile saline at neutral pH (100 µ l) containing 1 mM CaCl 2 , followed by administration of OXi4503 (40 mg kg −1 , 4 mg ml −1 ). Control mice were injected with 100 µ l saline. After 2 h, all mice were injected i.v. with 100 µ g lectin-AlexaFluor 568 diluted in sterile saline at neutral pH (100 µ l) containing 1 mM CaCl 2 . At 5 min after injection, mice were culled and underwent perfusion fixation, as described above.
Optical clearing and imaging. Following perfusion fixation, tumours were resected and rinsed three times in PBS, for 10 min each, and before optical clearing, to remove residual formaldehyde and avoid over-fixation 66 . After PBS rinsing, tumours were optically cleared with BABB (1:2 benzyl alcohol: benzyl benzoate) 67 . The BABB optical clearing preparation consisted of dehydration in methanol for 48 h followed by immersion in BABB for 48 h (ref. 16 ).
Fluorescently labelled tumour vasculature in cleared tissue was visualized with OPT (Bioptonics, MRC Technologies). Lectin-AlexaFluor 647 was imaged using a filter set with excitation range of 620/60 nm and emission of 700/75 nm. For vessels labelled with lectin-AlexaFluor 568, a filter set with excitation at 560/40 nm and emission at LP610 nm was used. Measurements were performed with an exposure time of 1,600-2,000 ms for lectin-AlexaFluor 647 and 270-600 ms for lectin-AlexaFluor 568, which was varied according to sample size. The rotation step was 0.45°. The final resolution ranged from 4.3 μ m to 8 μ m, depending on the sample size 68 .
OPT data were reconstructed with Nrecon (Bruker). Misalignment compensation was used to correct misalignment during projection image acquisition to reduce tails, doubling or blurring in the reconstructed image. The depth of correction for ring artefact reduction was 4 and defect pixel masking was 50% for all scans.
Image processing and vessel segmentation.
Reconstructed OPT data were used to generate whole-tumour blood vessel networks. First, a 3D Gaussian filter with a width of 50 pixels (corresponding to a physical size of 300 µ m, greater than the largest vessel diameter) was applied. The filtered data were subtracted from the original data to remove background variations in autofluorescence. A 3D Frangi filter was then applied (Matlab, MathWorks) to enhance vessel-like structures 17 . The response to the filter was thresholded to segment blood vessels from background. Skeletonization of these thresholded data was performed in Amira (Thermo Fisher Scientific), which also converted the data into graph format (that is nodes and segments with associated radii). To ensure that vessel structures were accurately represented, 2D sections from the original image data were swept through reconstructed 3D networks (in Amira), with visual inspection used for accordance between vessel location and thickness, and the location of the fluorescence signal.
Mathematical model of steady-state tissue fluid dynamics. Blood flow through the segmented vascular network was modelled by Poiseuille's law, using empirically derived laws for blood viscosity (assuming constant network haematocrit) and following the established approach developed in refs 69, 70 and applied to numerous tissues (for example, mesentery 71, 72 , muscle 73 , cortex 74 and tumours 54, 75 ). This model assumes conservation of flux at vessel junctions to define a linear system to solve for the pressures at nodal points in the network (from which vessel fluxes are calculated using Poiseuille). Boundary conditions on terminal nodes in the network were estimated using the optimization method of ref. 72 , which matches the network solution to target mean shear stress and pressure values.
The approach of ref. 72 requires a proportion of boundary conditions to be applied to a microvascular network. However, neither flow or pressure measurements were obtained in individual vessels in vivo for our tumour networks. As such, an optimization procedure was employed to induce a physiological pressure drop (55 to 15 mm Hg for both LS147T and SW1222 simulations) across peritumoral boundary vessels in a network. Consistent with previous studies 76, 77 , 33% of internal nodes were assigned zero flow with all remaining boundary nodes determined using the optimization algorithm of ref. 72 . This procedure was repeated until simulations ensured physiologically realistic tissue perfusion when compared to that gathered in vivo using ASL-MRI.
The network flow solution was coupled to an interstitial fluid transport model, adapting the approach taken in ref. 78 to model oxygen delivery to tissue. The interstitium is modelled as a porous medium using Darcy's law:
subject to p → p I as |x| → ∞ . Here, u is the volume-averaged IFV, p is the IFP, p I is the target IFP, and κ is the hydraulic conductivity of the interstitial tissue. Starling's law is used to describe fluid transport across the endothelium, from the vessels into the interstitium:
where, q is the fluid flux across the endothelium, L p is the hydraulic conductance of the vessel wall, S is the surface area of the vasculature, σ is the oncotic reflection coefficient, and Δ p and Δ Π are the fluid and oncotic pressure gradients between the vasculature and tissue. To solve the model computationally, we discretized the tumour vasculature into a series of M sources of strength q s,j so that the conservation of mass equation is modified to 
Starling's law, equation (2), can be written in the form
where p v,i and Π v,i are the blood and oncotic pressure at the vessel wall, p b,i and Π b,i are the intravascular blood pressure in the absence of diffusive interstitial fluid transfer (calculated using the Poiseuille flow model) and oncotic pressure, and q v,i is the rate of fluid flow per unit volume from blood vessel i to the interstitium. The intravascular resistance to fluid transport is defined by K = 1/L p S. Equations (5), (6) and (7) were combined to form a dense linear system, which was solved to give the IFP field throughout the tissue. Parameter values for the complete mathematical model are shown in Supplementary Table 2 .
Mathematical model of time-dependent vascular and interstitial transport.
A 'propagating front' (PF) algorithm was developed to describe the transport of solute (for example, a drug) through the tumour vessel network and interstitium. This model considers the timescale for delivery of a drug, on which the flow problem is assumed to be steady (the timescales for drug transport by advection and diffusion are much faster than those for vascular adaption, which would contribute to a non-steady flow solution). A vascular input function was first defined, which describes the time-dependent delivery of the drug concentration into the network, and which then propagates throughout the network according to the network topology and flow solution. The influence of each vessel network inlet was modelled independently and each solution linearly superimposed, allowing the algorithm to be parallelized.
Each node was assigned a set of values, J describing the ratio of the flow in each vessel segment connected to the node (F) to the total inflow into the node (F in ). Flow values were taken from the steady-state model defined above. The J values were propagated through the network, following pathways with decreasing vascular pressure. Using velocities from the steady-state solution, delays (d) were also assigned to each vessel segment. Vessel segments attached to each node were categorized as outflows (negative pressure gradient) or inflows (positive pressure gradient). Time-dependent drug concentration in the kth outflowing vessel segment (C k (t)) was modelled as
where C j (t) is the concentration in the jth inflowing vessel segment, and N is the total number of inflowing vessel segments.
Interstitial delivery was cast in a forward finite difference framework, in which vessels were considered as radial emitters. Points were gridded on concentric cylinders, regularly spaced around the vessel segment (with spacing ranging from 10 to 100 µ m). Exchange of the drug across the vessel wall and diffusion through the interstitium were modelled as
where + C j i 1 is the interstitial concentration at the jth time point (at a radial distance r from the vessel) and C j v is the vascular concentration. Interstitial velocity and pressure were not used in the time-dependent model, for simplicity, but could be incorporated in future studies, which could be particularly relevant for simulating the delivery of large molecules. Coefficient A is a 2D square matrix of dimension n, where n is the number of radial positions in the interstitial finite difference calculation, h is their radial separation and k is the spacing between time steps:
Here, D is the diffusion coefficient of the agent under investigation. Following each finite difference step, interstitial diffusion solutions were regridded to a 64 × 64 × 64 matrix (~100 µ m isotropic resolution) for storage. During regridding, molar quantities were converted to molar concentration, with parameter Γ controlling transport across the vessel wall
P in which, for small molecules, transport was assumed to be diffusive, and pressure terms were assumed to be negligible.
Measurement of vessel network functional connectivity and redundancy.
The mean number of viable alternative pathways, N, for each node if the shortest path (based on transit time-incorporating flow velocity) was occluded was used to define the redundancy of tumour vessel networks, alongside r, the average additional distance that would be travelled 79 . Connectivity was defined as the sum of the number of nodes upstream and the number of nodes downstream of a given node, divided by the total number of nodes in the network. All three measures reflect functional connectivity (that is, following pathways with decreasing vascular pressure from steady-state fluid dynamics simulations), and were estimated from vessel networks using algorithms written in house in Python 2.7.
Simulation of Gd-DTPA delivery. The systemic pharmacokinetics for Gd-DTPA in mice, following an i.v. bolus injection, were modelled as a biexponential decay:
v m t mt 1 2 1 2 with a 1 = 2.55 mM, m 1 = 8 × 10 −2 s −1 , a 2 = 1.2 mM and m 2 = 1 × 10 −3 s −1 (ref. 27 ).
Measurement of vessel network functional connectivity and redundancy. The mean number of viable alternative pathways, N, for each node if the shortest path (based on transit time-that is incorporating flow velocity) was occluded was used to define the redundancy of tumour vessel networks, alongside r, the average additional distance that would be travelled 79 . Connectivity was defined as the sum of the number of nodes upstream and the number of nodes downstream of a given node, divided by the total number of nodes in the network. All three measures reflect functional connectivity (that is following pathways with decreasing vascular pressure from steady-state fluid dynamics simulations), and were estimated from vessel networks using algorithms written in house in Python 2.7.
Simulation of Gd-DTPA delivery. The systemic pharmacokinetics for Gd-DTPA in mice, following an i.v. bolus injection, were modelled as a biexponential decay: Simulation of OXi4503 delivery. OXi4503 systemic pharmacokinetics were modelled as a single exponential function, of the form
v R t max 1 2 with R 1/2 = 3.1 × 10 −5 s −1 and C max = 7.7 µ M (ref. 34 ). This assumed a mouse mass of 25 g and injection dose of 40 mg kg −1 .
Dynamic contrast-enhanced MRI. Gd-DTPA (Magnevist, Bayer) was injected as a bolus into mouse tail veins using a power injector (Harvard Instruments). We injected 5 ml kg −1 over a period of 5 s, which was initiated at 90 s after the start of a dynamic, spoiled gradient-echo sequence (echo time, 2.43 ms; repetition time, 15 ms; flip angle, 20°; five slices; slice thickness, 0.5 mm; matrix size, 128 × 128; field of view, 35 × 35 mm; temporal resolution 16 s; total duration 15 min). The change in signal intensity induced by the contrast agent was calculated by subtracting the mean signal from the first five frames of the acquisition.
Signal intensity was converted to Gd concentration via the change in longitudinal relaxation rate R 1 and contrast agent relaxivity (c 1 fixed at 2.9 mM −1 s −1 ):
was estimated from the theoretical change in spoiled gradient-echo signal magnitude 80 . R 10 was the mean, pre-enhancement R 1 , which was estimated from a Look-Locker multi-inversion time acquisition 81 , acquired before the dynamic sequence (TE, 1.18 ms; inversion time spacing, 110 ms; first inversion time, 2.3 ms; 50 inversion recovery readouts).
Contrast agent uptake data were fitted to a phenomenological model of the form
where S 0 , r 1 , r 2 and t 0 were fitted parameters. Fitting was performed in Python 2.7 (leastsq algorithm from the scipy package).
ASL-MRI. ASL data were acquired with a flow-sensitive alternating inversion recovery (FAIR) Look-Locker ASL sequence, with a single-slice spoiled gradient echo readout (echo time, 1.18 ms; inversion time spacing, 110 ms; first inversion time, 2.3 ms; 50 inversion recovery readouts; four averages) 9,81 . Regional perfusion maps were calculated as described by ref. 38 , with an assumed blood-partition constant of 0.9. Corresponding author(s): Simon Walker-Samuel
Statistics

Reporting Summary
Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
Optical Projection Tomography data were reconstructed using 64-bit NRecon (Bruker, Skyscan) (non-versioned software). REANIMATE simulations were performed using in-house software, written in Python 3.6 and C++; Github-repository details are provided in the manuscript.
Data analysis
Data were analysed using in-house software written in Python 2.7 and 3.6; Github-repository details are provided in the manuscript.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability
Raw data generated from this study can be found at http://doi.org/10.17605/OSF.IO/ZH9EU 2 nature research | reporting summary
April 2018
Field-specific reporting Please select the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/authors/policies/ReportingSummary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
This is an initial trial of a new technique and, as such, power calculations cannot be performed. Sample sizes were set based on standard approaches and practical considerations. Where appropriate, group sizes of 4 to 8 animals were used.
Data exclusions No data were explicitly removed from the analysis. Exclusion criteria included poor data quality (assessed via signal-to-noise measurements or the presence of image artefacts).
Replication
The study includes repeated measurements, both within tumour types and across different tumour types. All experiments were successful in the tumours studied.
Randomization Mice were randomly assigned to groups following inoculation with tumour cells.
Blinding
Both during data acquisition and during data analysis, researchers were blinded to the group membership of each mouse.
Reporting for specific materials, systems and methods Authentication LS174T cells were authenticated prior to purchase and SW1222 cells were authenticated by the ECACC. Both lines were authenticated using using PCR.
Mycoplasma contamination
All cells were regularly monitored for mycoplasma contamination. All tests were negative.
Commonly misidentified lines (See ICLAC register)
Neither of our cell lines are in the ICLAC database.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals [8] [9] [10] week old, female, immune-compromised nu/nu nude mice (background CD1)
Wild animals
The study did not involve wild animals.
Field-collected samples
The study did not involve samples collected from the field.
